Anadys Pharmaceuticals
About
Anadys Pharmaceuticals develops novel therapeutics for the treatment of chronic hepatitis C viral infections.
- 1 - 10
Details
- Last Funding Type
- Private Equity（PE）
- Last Funding Money Raised
- $71.30M
- Industries
- Biotechnology,Health Care
- Founded date
- Jan 1, 1992
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Anadys Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic hepatitis C viral infections.The company focuses on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7 or TLR7.Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. As of November 22, 2011, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 11, 2005 | Private Equity（PE） | $71.30M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Private Equity（PE） |
|
|
— | Private Equity（PE） |
